Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB at TD Cowen Health Care Conference Transcript

Mar 06, 2023 - Mar 08, 2023 / 03:30PM GMT
Release Date Price: kr53.65 (-2.98%)
Unidentified Analyst

(audio in progress) who's joining on the 43rd annual conference. I'm joined by the Hansa Biopharma management team, and I'll pass it over to them to walk through their presentation.

SÃ;ren Tulstrup
Hansa Biopharma AB - President & CEO

¸ -

Thanks so much for the intro and thank you everyone for your interest in Hansa Biopharma. It's great to be back in real life here at the Cowen conference after a three-year break.

Before I start my presentation, just the usual warning that my presentation today contains forward-looking statements, and therefore, you should apply appropriate caution.

Now, for those of you who are not completely familiar with Hansa Biopharma, here's a snapshot overview of the company. We're founded back in 2007 as a spin out from Lund University in southern Sweden. And what led to the foundation of the company was the discovery of an enzyme which today is known as imlifidase, which has the unique property that it very fast and effectively cleaves immunoglobulin G.

If you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot